Member Info for Rocka

Down to. 2.76% so they probably have 3m shares to shift around £330k at 11p i am sure they are selling more than 20k shares a day so as soon as they are oit think we’lk be bCk over. 20p

As for the poster who thinks most would accept a 25p takeover, i think you’ll find this not to be the case, most know the potential here, and the bod would be very bad businessmen to accept 25p not even close

Hope you’re right gtc, apart from this it’s all looking good. I remain confident in my investment here. We are in a better position than we were when this was 20p so fingers crossed

Watched again, nci agreement runs out 28th Nov, a questioner asked if nci will lose access if they dont renew, Adrian they would but we wouldnt necessarily pull the plug straightaway, i am confident but its weird that the nci sont seem keen to renew as its days away.. your thoughts?

I bought more today and will continue to buy as many as i can get my hands on, funds permitting.

Most of out conpetitors like hemo have a mc of £30, £40 and £50m we are undervalued without a doubt. Even at this stage this shpuld be north of 40p imo

Still think 50p by year end is possible time will tell

You say some are selling but look at the trades, most are actually buying

Takeover at 25p you say? No chance wouldn’t be acceptable to most as you said. Will need to be at least double that imo

Yep 65p sounds like a reasonable price at this stage.

£3m without optimal, with Optimal?? Sky’s the limit!

Fusion Antibodies’ (FAB.L) interim results highlight impressive progress, given its limited

resources and the difficult trading environment in the reporting period (April-

September). The receipt of two grant awards has allowed Fusion to offset some overhead

costs, increase R&D spend and lease some capital items ahead of the planned commercial

launch of OptiMAL next month. The results themselves were in line with the trading

statement last month and our FY26 forecasts are broadly unchanged. We continue to see

a significant recovery with revenue in H2 (to £1.4m, +86%) with trading helped by the

improving environment in biotech. With improvements in gross margin and tight cost

control/working capital management, our model indicates Fusion has a cash runway into

FY27. We tentatively indicate revenues for FY27 to be c. £3m without assuming any

material contribution from OptiMAL.

If so any guesses what the company would accept to sell the company? Sp?

this has huge potential and i really like the ceo too, he isn’t a bull****ter like the vast majority on aim and they truly have something transformational.

Great price, been buying recently but not at this price, this is a steal. If i had more today i’d be throwing it all in FAB, what A fabulous company this is. Waiting on some funds tomorrow, hopefully i can get a good price

I think with optimal. We can do £10m plus revenue and i’m being conservative, just my opinion.

Some decent buys this morn

It is that’s just pre launch what will the pipeline be post launch, £10m, £20m probable.

£3m forecast and that’s without optimal, imagine what it would be with opti. This will rocket, just need the nci extension deal signed and waiting eagerly for the optimal launch.